Reports & eBooks

Drug Pipeline & Clinical Update - February 2024

March 7, 2024

Capital Rx


  • Three key new drug approvals, all "first" of their respective kinds
  • Three notable expanded indications
  • Six generic launches
  • Capital Rx's Updated Drug Recall Report: CLICK HERE to review

Capital Rx's Clinical Team closely monitors the drug landscape to provide our clients with timely information on newly FDA-approved medications, as well as products in the pipeline. Read on to review our February 2024 Monthly Drug Update!

Key New Drug Approvals

Eohilia™ (budesonide) oral suspension

Approval Date: 02/12/2024 - CLICK HERE for the press release

Indication: Eosinophilic esophagitis

Cost*: $37.50 per packet

Key Considerations:

Aurlumyn™ (iloprost) intravenous injection

Approval Date: 02/14/2024 - CLICK HERE for the press release

Indication: Severe frostbite

Cost*: TBD

Key Considerations:

Amtagvi™ (lifileucel) intravenous infusion

Approval Date: 02/16/2024 - CLICK HERE for the press release

Indication: Unresectable or metastatic melanoma

Cost*: $515,000 per one-time infusion

Key Considerations:

Notable Expanded Indications

Onivyde® (irinotecan liposome injection) intravenous injection - expanded to be used with oxaliplatin, fluorouracil, and leucovorin, for first-line treatment of metastatic pancreatic adenocarcinoma.

Tagrisso® (osimertinib) tablet - expanded to be used with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected.

Xolair® (omalizumab) subcutaneous injection - expanded to be used for the reduction of accidental allergic food reactions, including anaphylaxis, in adults and children ages 1 year and older.

Generic Launches

Korlym® (mifepristone 300mg) tablet

Gralise® (gabapentin 300mg, 600mg) once-daily tablet

BromSite® (bromfenac 0.075%) ophthalmic solution

Pradaxa® (dabigatran 110mg) capsule

Emflaza® (deflazacort 6mg, 18mg, 30mg, 36mg) tablet

Alrex® (loteprednol 2%) ophthalmic suspension

Contact Us if you'd like to learn more about Capital Rx's full-service pharmacy benefit management (PBM) solutions and clinical programs.


* Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support

DOWNLOAD NOWBack to Insights

Sign up for our newsletter!

Get the latest information on JUDI news, webinars, and industry insights through our newsletter. Sign up now!